-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
NGM BIOPHARMACEUTICALS INC quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and change rate from 2017 to Q4 2023.
- NGM BIOPHARMACEUTICALS INC Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 31 Dec 2023 was -$27.6M, a 23% increase year-over-year.
- NGM BIOPHARMACEUTICALS INC Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending 31 Dec 2023 was -$142M, a 12.8% increase year-over-year.
- NGM BIOPHARMACEUTICALS INC annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2023 was -$142M, a 12.8% increase from 2022.
- NGM BIOPHARMACEUTICALS INC annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$163M, a 35.2% decline from 2021.
- NGM BIOPHARMACEUTICALS INC annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$120M, a 17.5% decline from 2020.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Change (%)